Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-based Therapeutics
2014 Press Releases
1/3/2014
Marina Biotech Announces Organizational Changes
1/9/2014
Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES® Nucleic Acid Delivery Technology
1/14/2014
Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology
1/23/2014
Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan
2/24/2014
Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company’s Promissory Note
2/27/2014
Marina Biotech Continues to Build Worldwide Patent Protection for its SMARTICLES® Nucleic Acid Delivery Technology
3/11/2014
Marina Biotech to use its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases
4/2/2014
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-based Diagnostics and Therapeutics for Rare Diseases
5/6/2014
Marina Biotech Presents Clinical Data Demonstrating Delivery of both Single and Double-Stranded Nucleic Acids to Tumors